BiotechTube
Home/Pipeline/CAR-T Program (Hematological)

CAR-T Program (Hematological)

B-cell Malignancies

Phase 1Active

Key Facts

Indication
B-cell Malignancies
Phase
Phase 1
Status
Active
Company
XellSmart

About XellSmart

A Chinese biotech developing next-generation CAR-T and CAR-NK cell therapies for oncology and immunology applications.

View full company profile

Therapeutic Areas

OncologyImmunology

Other B-cell Malignancies Drugs

DrugCompanyPhase
BAFFR Allo CAR-NK CellsPeproMene BioPre-clinical
IKS03Iksuda TherapeuticsClinical
TNB-486Ancora BioPhase 1
docirbrutinib (AS-1763)Carna BiosciencesPhase 1b
AbivertinibSorrento TherapeuticsPhase 1/2
Kymriah® (tisagenlecleucel)NovartisApproved
KITE-363Gilead SciencesPhase 1/2
HSK29116Haisco Pharmaceutical GroupPhase I/II
TG-1701TG TherapeuticsPhase 1
TG-1801TG TherapeuticsPhase 1
REC-3565Recursion PharmaceuticalsPhase 1
Plamotamab (XmAb®13676)XencorPhase 2